Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

Published:2024-09 Issue:9 Volume:25 Page:1147-1162
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Raghav Kanwal,Siena Salvatore,Takashima Atsuo,Kato Takeshi,Van den Eynde Marc,Pietrantonio Filippo,Komatsu Yoshito,Kawakami Hisato,Peeters Marc,Andre Thierry,Lonardi Sara,Yamaguchi Kensei,Tie Jeanne,Castro Cristina Gravalos,Hsu Hung-Chih,Strickler John H,Kim Tae-You,Cha Yongjun,Barrios Daniel,Yan Qi,Kamio Takahiro,Kobayashi Kojiro,Boran Aislyn,Koga Makito,Allard John D,Yoshino Takayuki

Publisher

Elsevier BV

Reference33 articles.

1. HER2-low expression in patients with advanced or metastatic solid tumors;Uzunparmak;Ann Oncol,2023

2. HER2/neu testing in primary colorectal carcinoma;Ingold Heppner;Br J Cancer,2014

3. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis;Nam;PLoS One,2016

4. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer;Sawada;Clin Colorectal Cancer,2018

5. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer;Raghav;JCO Precis Oncol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

2. Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?;The Lancet Oncology;2024-09

3. When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan;Cancer;2024-08-25